Robert W. Baird analyst Garrett Holland maintained a Hold rating on Expeditors International (EXPD – Research Report) on August 3 and set a price target of $110.00. The company’s shares closed last Thursday at $103.55.
According to TipRanks.com, Holland is a 3-star analyst with an average return of 4.8% and a 60.0% success rate. Holland covers the Industrial Goods sector, focusing on stocks such as Knight Transportation, Old Dominion Freight, and Schneider National.
Expeditors International has an analyst consensus of Moderate Sell, with a price target consensus of $106.75, implying a 3.2% upside from current levels. In a report issued on August 3, Cowen & Co. also reiterated a Hold rating on the stock with a $125.00 price target.
Based on Expeditors International’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.66 billion and net profit of $346 million. In comparison, last year the company earned revenue of $3.2 billion and had a net profit of $287 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Expeditors International of Washington, Inc. engages in the provision of global logistics services. The firm offers airfreight, ocean freight and ocean and customs brokerage and other services. It also provides customer solutions such as order management, time-definite transportation, warehousing and distribution, temperature-controlled transit, cargo insurance and customized logistics solutions. The company was founded by John M. Kaiser, Peter Rose, Wang Li Kou, Kevin Walsh, Hank Wong, George Ho, Robert Chiarito, and Glenn Alger in May 1979 and is headquartered in Seattle, WA.
Read More on EXPD:
- Moderna (MRNA) Receives a Sell from SVB Securities
- Robert W. Baird Reaffirms Their Hold Rating on Astec (ASTE)
- Forma Therapeutics Holdings (FMTX) Receives a Buy from SVB Securities
- Guardant Health (GH) Receives a Buy from SVB Securities
- Aclaris Therapeutics (ACRS) Gets a Buy Rating from SVB Securities